Romidepsin
Myeloid Malignancy
University of California, San FranciscoSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Myeloid Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Venetoclax First Affiliated Hospital of Zhejiang University | Phase 3 | BB |
ETOPOSIDE University of California, San Francisco | Phase 3 | BB |
Vesanoid Ascentage Pharma Group Inc. | Phase 3 | BB |
Arsenic Trioxide Ruijin Hospital | Phase 3 | BB |
Decitabine Benjamin Tomlinson | Phase 2 | BB |
View all 22 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →